1,598
Views
0
CrossRef citations to date
0
Altmetric
Article

The effect of vitamins B12, B6 and folate supplementation on homocysteine metabolism in a low-income, urbanised, black elderly community in South Africa

, & ORCID Icon
Pages 162-167 | Received 25 May 2020, Accepted 03 Nov 2021, Published online: 16 Dec 2021

References

  • Rehan F, Qadeer A, Bashir I, et al. Risk factors of cardiovascular disease in developing countries. International Current Pharmaceutical Journal. 2016;5(8):69–72.
  • Charlton KE, Ferreira M, Plessis LMD. The nutritional status and needs of older persons. In: Steyn NP, Temple NJ, editor. Community nutrition textbook for South Africa: a rights-based approach. Cape Town: Tygerberg, South Africa: Chronic Diseases of Lifestyle Unit, Medical Research Council; 2008:553–596.
  • Kelly G, Mrengqwa L, Geffen L. “They don’t care about us”: older people’s experiences of primary healthcare in Cape Town, South Africa. BMC Geriatr. 2019;19(1):98.
  • Oldewage-Theron WH, Egal AA, Grobler CJ. Is obesity associated with iron status in the elderly? A case study from sharpeville, South Africa. Public Health Nutr. 2015;18(3):521–9.
  • Oldewage-Theron WH, Salami L, Zotor FB, et al. Health status of an elderly population in sharpeville, South Africa. Health SA Gesondheid. 2008;13(3):15–17.
  • Otitoola O, Oldewage-Theron W, Egal A. Trends in the development of obesity in elderly day care attendees in sharpeville, South Africa, from 2007–2011. South African Journal of Clinical Nutrition. 2015;28(1):12–7.
  • McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56(1):111–28.
  • McCully KS. Homocysteine and the pathogenesis of atherosclerosis. Expert Rev Clin Pharmacol. 2015;8(2):211–9.
  • Ganguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. Nutr J. 2015;14(1):6.
  • Jin P, Bian Y, Wang K, et al. Homocysteine accelerates atherosclerosis via inhibiting LXRα-mediated ABCA1/ABCG1–dependent cholesterol efflux from macrophages. Life Sci. 2018;214:41–50.
  • Tinelli C, Di Pino A, Ficulle E, et al. Hyperhomocysteinemia as a risk factor and potential nutraceutical target for certain pathologies. Front Nutr. 2019;6(49):1–13.
  • de Koning EJ, van der Zwaluw NL, van Wijngaarden JP, et al. Effects supplementation of Two-year on vitamin depressive B12 and symptoms folic acid and quality of Life in older adults with elevated homocysteine concentrations: additional results from the B-PROOF study, an RCT. B-Vitamins and One-Carbon Metabolism. 2018;142:1–16.
  • Elbarbary NS, Ismail EAR, Zaki MA, et al. Vitamin B complex supplementation as a homocysteine-lowering therapy for early stage diabetic nephropathy in pediatric patients with type 1 diabetes: A randomized controlled trial. Clin Nutr. 2020;39(1):49–56.
  • Morley JE, Thomas DR. Geriatric nutrition. Boca Raton: CRC press; 2007.
  • Wang B, Wu H, Li Y, et al. Effect of long-term low-dose folic acid supplementation on degree of total homocysteine-lowering: major effect modifiers. Br J Nutr. 2018;120(10):1122–30.
  • van-der-Griend R, Biesma DH, Haas FJLM, et al. The effect of different treatment regimens in reducing fasting and postmethionine-load homocysteine concentrations. J Intern Med. 2000;248:223–9.
  • Avert. HIV and AIDS in South Africa. Available from: www.avert.org. [Accessed 6 December 2021].
  • Institute of Medicine Standing Committee on the Scientific Evaluation of Dietary Reference I. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. Washington DC: National Academies Press (US); 1998.
  • Azad MAK, Huang P, Liu G, et al. Hyperhomocysteinemia and cardiovascular disease in animal model. Amino Acids. 2018;50(3):3–9.
  • Chernyavskiy I, Veeranki S, Sen U, et al. Atherogenesis: hyperhomocysteinemia interactions with LDL, macrophage function, paraoxonase 1, and exercise. Ann N Y Acad Sci. 2016;1363(1):138–54.
  • Kaul S, Zadeh AA, Shah PK. Homocysteine hypothesis for atherothrombotic cardiovascular disease: not validated. J Am Coll Cardiol. 2006;48(5):914–23.
  • Lai WKC, Kan MY. Homocysteine-Induced endothelial dysfunction. Ann Nutr Metab. 2015;67(1):1–12.
  • Chrysant SG, Chrysant GS. The current status of homocysteine as a risk factor for cardiovascular disease: a mini review. Expert Rev Cardiovasc Ther. 2018;16(8):559–65.
  • Sreckovic B, Sreckovic VD, Soldatovic I, et al. Homocysteine is a marker for metabolic syndrome and atherosclerosis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2017;11(3):179–82.
  • Jamison RL, Hartigan P, Kaufman JS, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA. 2007;298(10):1163–70.
  • Martí-Carvajal AJ, Solà I, Lathyris D, et al. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2017;8:1–106.
  • Lan X, Zhou Z, Dang S, et al. Effect of supplementation with folic acid and B vitamins on cardiovascular outcomes: a meta-analysis of randomised controlled trials. The Lancet. 2017;390:S83.
  • Yanping L, Tianyi H, Yan Z, et al. Folic acid supplementation and the risk of cardiovascular diseases: A meta-analysis of randomized controlled trials. J Am Heart Assoc. 2017;5(8):1–8.
  • Gibson RS. Principles of nutritional assessment. In: Illustrated, Oxford: Oxford University Press; 2005:1–908.
  • Hoffbrand AV, Catovsky D, Tuddenham EGD, et al. Postgraduate haematology. 6th ed. Chichester: Wiley-Blackwell; 2011.